TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

KILL Teva Announces Launch of Generic Epzicom® Tablets in the United States

Teva Pharmaceutical Industries Ltd. requests that their press release NewsItemId: 20160928005512 entitled “Teva Announces Launch of Generic Epzicom® Tablets in the United States” be killed.

The release was issued by Teva Pharmaceutical Industries Ltd. without final FDA approval.

A replacement release will be issued at a later time.

EN
28/09/2016

Underlying

TEVA.NTeva Pharmaceutical Industries Limited Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva Releases Q2 2025 Aide Memoire

Teva Releases Q2 2025 Aide Memoire TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website. Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of ...

June 26, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial ...

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance to obtain a local or toll-free phone number and your personal pin. A l...

June 25, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Abschließende Daten aus der realen PEARL-Studie von Teva untermauern d...

Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne Die abschließende Analyse der realen PEARL-Studie für die Migräneprävention wurde auf dem 11. Kongress der European Academy of Neurology (EAN 2025) in Helsinki präsentiert1,2Fremanezumab demonstrierte eine langfristige Wirksamkeit und ein günstiges Sicherheits- und Verträglichkeitsprofil über den zweijährigen Untersuchungszeitraum1,2Über die gesamte Studie wurde eine hohe Injektionsadhärenz eingehalten (~90 %), gl...

June 24, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Les données définitives de l’étude PEARL menée par Teva en conditions ...

Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique L’analyse finale de l’étude PEARL ciblée sur la prévention de la migraine en conditions réelles a été présentée au 11ᵉ congrès de l’Académie européenne de neurologie (le congrès EAN 2025) qui s’est tenu à Helsinki1,2Le frémanézumab a montré une efficacité durable ainsi qu’un profil d’innocuité et de tolérabilité favorable au cours de la période d’étude de deux ans1,2L’observance des injections est...

June 24, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term ...

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period1,2Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration1 TEL AVIV, Israel, ...

June 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch